BridgeBio (BBIO) CEO Neil Kumar Exercises RSUs; $2.89M Tax Withholding

What Happened

• Neil Kumar, CEO of BridgeBio Pharma (BBIO), had 71,217 restricted stock units (RSUs) convert into common shares on August 16, 2026. Of those shares, 36,237 were withheld to satisfy tax obligations at $79.86 per share, producing a tax-withholding value of $2,893,887. The net result was issuance of 34,980 shares to Kumar.
• This was not an open-market sale. The withheld shares represent tax withholding in connection with RSU vesting (routine administrative/tax event), not a directional bet on the stock.

Key Details

• Transaction date: August 16, 2026. Form 4 filed August 18, 2026 (filed within the normal 2-business-day window).
• Shares vesting / converted: 71,217 RSUs converted to 71,217 common shares (recorded as exercise/conversion of a derivative, code M).
• Tax withholding: 36,237 shares withheld at $79.86/share for taxes (code F); total value withheld = $2,893,887.
• Net shares delivered to insider: 34,980 shares (71,217 vested − 36,237 withheld).
• Shares owned after transaction: not specified in the filing.
• Relevant filing notes: F1–F3 explain RSU mechanics and beneficial-ownership disclaimers; F2 explicitly states withheld shares satisfied tax obligations; F6–F9 describe the RSU vesting schedule; F4–F5 relate to trust-held shares and disclaimers of beneficial ownership.

Context

• Transaction codes: M = exercise/conversion of derivative (here, RSUs converting to shares on vesting); F = shares withheld to pay tax liabilities. This is effectively a cashless tax-withholding on RSU vesting, a common administrative step and not a market sale.
• For retail investors: tax-withholdings on vested awards are routine and do not necessarily signal insider buying or selling intent. The meaningful dollar figure here is the tax withholding (~$2.89M), not a sale proceeds amount.